Significant and insignificant associations between
Abstract
The Rho‐kinase (ROCK) family members, consisting of ROCK1 and ROCK2, are serine‐threonine kinases that are activated by small GTPases. ROCKs play central roles in the actin cytoskeleton organization and regulate a wide range of fundamental cellular functions, such as apoptosis, inflammatory responses, cell contractility, adhesion, migration, motility, proliferation, phagocytosis, and apoptosis. Accumulating evidence from basic and clinical studies supports the concept that ROCK plays important roles in many diseases and could be a potential therapeutic target for diverse disorders, including cardiovascular, neurologic, metabolic, autoimmune disorders, and cancers. Although there are only limited numbers of published studies related to ROCK polymorphisms in humans, the contribution of the genetic studies related to ROCK variants to the disease states is emerging. Identifying mutated genes or associated polymorphisms and evaluating their potential risks are important steps for understanding the genetic components and pathogenesis of diseases. Identification of functional mutations or polymorphisms could potentially help in the development of novel ROCK‐specific therapies in related disease states.
Keywords
- disorder
- polymorphism
- Rho‐kinase
- ROCK
- variant
1. Introduction
Rho‐kinase (ROCK) is a serine/threonine kinase that is activated by small Rho GTPase proteins. Two ROCK isoforms have been identified: ROCK1 and ROCK2. These ROCK isoforms are encoded by separate genes on human chromosomes 18q11.1 (ROCK1) and 2p24 (ROCK2). ROCK1 and ROCK2 enzymes contain 1354 and 1388 amino acids, respectively [1, 2]. Two isoforms have ∼65% overall amino acid homology and ∼92% homology in the kinase domain. The carboxy terminus of ROCK folds back onto the kinase domain, thereby forming an autoinhibitory loop that maintains the enzyme in an inactive state. Binding of GTP‐bound, biochemically active Rho (such as RhoA/RhoB/RhoC) to the Rho‐binding domain (RBD) disrupts the negative regulatory interaction between the catalytic domain and the autoinhibitory C‐terminal region, resulting in activation of the enzyme in response to extracellular signals [1, 2]. On the other hand, RhoE interacts with the N‐terminal region of ROCK1 and prevents Rho binding to RBD [3]. ROCK1 is cleaved by caspase‐3, but ROCK2 can be cleaved by granzyme B or caspase‐2 (Figure 1) [1, 2]. ROCK enzymes are likely to exist as dimers by parallel association at the coiled‐coil domain and the dimerized kinase domain of ROCK appears to be in an active conformation in the absence of phosphorylation [4, 5].

Figure 1.
Schematic molecular structure and main regulators of ROCKs. ROCK sequences comprise a kinase domain located at the amino terminus of the protein, followed by a coiled‐coil region containing the Rho‐binding domain (RBD) and a pleckstrin homology (PH) domain with a cysteine‐rich domain (CRD).
Although ROCK1 and ROCK2 are ubiquitously expressed, ROCK2 is highly expressed in the brain and the heart, whereas ROCK1 is preferentially expressed in the lung, liver, spleen, kidney, and testis [1, 6]. ROCK signaling has been implicated in a wide range of fundamental cellular functions including cell morphology, contraction, adhesion, motility, migration, proliferation, differentiation, invasion, metastasis, and apoptosis [1, 2]. ROCK can also regulate macrophage phagocytic activity and endothelial cell permeability, and it is known to play a role in inflammatory mechanisms and endothelial dysfunction [7, 8].
2. ROCK polymorphisms and disease susceptibility
There are only limited numbers of published studies related to
2.1. Cancer
It has been demonstrated that
There are some controversial results about the association between the
Although there were no significant associations between
2.2. Cardiovascular diseases
Seasholtz et al. [17] reported that rs2230774 (Thr431Asn) polymorphism at
Significant associations were observed for GG genotype of rs978906, AA genotype of rs6753921, GG genotype of rs10495582, and AA genotype of rs2230774 (Thr431Asn) polymorphisms with high‐altitude essential hypertension in Indian high‐altitude native Ladakhi population [21]. Haplotype GAGA composed of variant alleles was found to be in higher proportion in cases [21]. Other six polymorphisms (rs2290156, rs10167277, rs10929727, rs6716817, rs4477886, and rs10929728) were also studied, but no marked changes were noted in this study [21]. Associations of
Peterson et al. [22] evaluated allelic variants [rs12622447, rs10929728, rs1868584, rs6716817, rs2230774 (Thr431Asn), rs5829297, rs4027164, and rs17366517] or haplotypic associations of
The major alleles of rs978906 (A allele) and rs2230774 (C allele) of
Yoo et al. [25] demonstrated that the genotype frequencies of five polymorphisms (rs978906, rs2271621, rs2230774, rs1515219 and rs3771106) of
No association of the
Palomino Doza et al. [27] investigated the role of genetic variations in
2.3. Autoimmune diseases
Significant differences between systemic sclerosis patients and control group were observed with regard to rs35996865 polymorphism of the
It has been reported that
There is also evidence that
2.4. Ocular diseases
There are only two published association studies related to
2.5. Ischemic stroke
In a large prospective study, associations of
2.6. Metabolic syndrome
2.7. Respiratory distress syndrome
There is evidence that
2.8. Kidney disease
It has been demonstrated that rs2230774 (Thr431Asn) polymorphism of
2.9. Overactive bladder
Gurocak et al. [38] found that genotype and allele frequencies were not significantly different between the children with overactive bladder and the control group for
2.10. Epilepsy
Association of the Thr431Asn polymorphism with idiopathic generalized epilepsy has been investigated in a study [39]. Genotype distributions and the allele frequencies for the Thr431Asn polymorphism showed no significant differences between the control and epilepsy groups. Moreover, this polymorphism did not influence age of epilepsy onset, family history, single or combined drug treatments, or status epilepticus [39]. Therefore, these results suggest that the Asn431
2.11. Migraine
Uslu Kuzudisli et al. [40] have investigated the association of the Thr431Asn polymorphism with migraine in a Turkish population. No statistically significant association between a migraine and genotype distributions or the allele frequencies for the
2.12. Diabetes
It has been reported that
2.13. High altitude pulmonary edema
Pandey et al. [41] investigated a total of 13
2.14. Psychiatric disorders
Tables 1 and 2 show the significant and insignificant associations of
Disease | Significant association | Ref. | Insignificant association | Ref. |
---|---|---|---|---|
Breast cancer | Y405*, S1126* | [10] | ||
Lung cancer | P1193S | [10] | rs11874761, rs8085504, rs2127958, rs17202375, rs288980 | [11] |
Gastric cancer | G285* | [12] | ||
Colorectal cancer | rs73963110, rs35996865 | [13] | rs35768389, rs73963110, rs2127958, rs288980 | [14] |
rs35996865 (in male patients) | [14] | |||
V1309* | [43] | |||
Clear cell renal cell carcinoma | rs35996865 | [16] | rs8089974, rs11874761 | [16] |
Tetralogy of Fallot | rs288979, rs56085230 (Tyr269Tyr) | [27] | rs2292296 (Leu1097Phe), rs7237677, rs7227454, rs288989, rs45449301 (Ile432Val), rs288979, rs17202368, rs17202375, rs2271255 (Lys222Glu), rs1481280, rs8085504, rs398528, rs112165707 (Ser595Ser), rs45562542 (Thr773Ser) | [27] |
Systemic sclerosis | rs35996865 | [28] | rs112108028 (Pro1164Leu), rs1045144 | [28] |
Behçet’s disease | rs73963110, rs111874856 (Val355Ile), rs112130712 (Lys1054Arg), rs112108028 (Pro1164Leu) | [30] | rs35996865, rs111312709 (Thr792Ala), rs2271255 (Lys222Glu) | [30] |
Primary open‐angle glaucoma | rs35996865 | [32] | ||
Ischemic stroke | rs7239317, rs2127958, rs1481280, rs1006881, rs11874761, rs10083915, rs11873284 | [33] | rs288980 | [33] |
Obesity‐related metabolic syndrome | rs35996865 | [34] | rs73963110, rs112108028 (Pro1164Leu), rs111312709 (Thr792Ala), | [34] |
Respiratory distress syndrome | rs2271255 (Lys222Glu), rs35996865 | [35] | rs73963110 | [35] |
Schizophrenia | rs8085654, rs288980, rs1481280 | [42] |
Table 1.
Disease | Significant association | Ref. | Insignificant association | Ref. |
---|---|---|---|---|
Breast cancer | rs2230774 (Thr431Asn) | [9] | rs1130757 (Arg83Lys) | [9] |
Gastric cancer | S457N | [12] | ||
Colorectal cancer | rs2290156, rs10178332, rs35768389, rs10929732, rs34945852 | [13] | rs965665, rs2230774, rs6755196, rs1515219 | [13] |
rs12692437, rs7563468, rs35768389, rs17463896, rs16857265 | [14] | |||
Mantle cell lymphoma | rs2290156, rs965665, rs10178332, rs2230774 (Thr431Asn), rs2230774 (Thr431Ser), rs6755196, rs726843 | [15] | ||
Hypertension | rs2230774 (Thr431Asn) | [17] | rs2230774 (Thr431Asn) | [19] |
rs965665, rs10178332, rs6755196, rs10929732 | [18] | rs978906, rs2230774 (Thr431Asn), rs56304104 | [20] | |
rs1868584 | [23] | |||
High‐altitude essential hypertension | rs978906, rs6753921, rs10495582, rs2230774 (Thr431Asn) | [21] | rs2290156, rs10167277, rs10929727, rs6716817, rs4477886, rs10929728 | [21] |
Preeclampsia | rs12622447, rs10929728, rs1868584, rs6716817, rs2230774 (Thr431Asn), rs5829297, rs4027164, rs17366517 | [22] | ||
Arterial stiffness | rs978906, rs2230774 (Thr431Asn) | [24] | ||
Vasospastic angina | GTCTG haplotype | [25] | rs978906, rs2271621, rs2230774, rs1515219, rs3771106 | [25] |
Cardiac septal defects | rs2230774 (Thr431Asn) | [26] | ||
Systemic sclerosis | rs10178332 | [28] | rs2230774 (Thr431Ser), rs2230774 (Thr431Asn), rs35768389 (Asp601Val), rs726843, rs2290156, rs965665, rs6755196, rs10929732 | [28] |
Behçet’s disease | rs35768389 (Asp601Val), rs1515219 | [29] | rs726843, rs2290156, rs965665, rs10178332, rs2230774, rs6755196, rs10929732, rs34945852 | [29] |
Rheumatoid arthritis | rs1868584 | [23] | ||
Diabetic retinopathy | rs2230774 (Thr431Asn), rs1130757 (Arg83Lys) | [31] | ||
Primary open‐angle glaucoma | rs2290156, rs965665, rs10178332, rs2230774 (Thr431Asn), rs2230774 (Thr431Ser), rs6755196, rs726843 | [32] | ||
Ischemic stroke | rs921322, rs8996, rs6753921, rs2230774, rs1515219, rs6716817, rs10203916, rs6755337, rs12622447 | [33] | ||
Obesity‐related metabolic syndrome | rs2230774 (Thr431Asn) | [34] | rs2230774 (Thr431Ser), rs726843, rs2290156, rs965665, rs10178332, rs6755196 | [34] |
Respiratory distress syndrome | rs726843, rs2290156, rs10178332, rs35768389 (Asp601Val) | [35] | rs1515219, rs965665, rs2230774 (Thr431Asn), rs6755196, rs10929732 | [35] |
Chronic kidney disease | rs2230774 (Thr431Asn) | [36] | ||
Urinary albumin excretion | rs1515219, rs2290156 | [37] | ||
Overactive bladder | rs2230774 (Thr431Asn) | [38] | ||
Idiopathic generalized epilepsy | rs2230774 (Thr431Asn) | [39] | ||
Migraine | rs2230774 (Thr431Asn) | [40] | ||
Diabetes | rs1868584 (with type‐1 diabetes) | [23] | rs2230774 (Thr431Asn), rs1130757 (Arg83Lys) | [31] |
High altitude pulmonary edema | rs10929728 | [41] | rs978906, rs6753921, rs2290156, rs10495582, rs2230774, rs10167277, rs13393192, rs10929727, rs6716817, rs4477886, rs41264193, rs12622447, rs10929728 | [41] |
Bipolar disorder | rs1868584 | [23] |
Table 2.
Significant and insignificant associations between
3. Structure or function of the ROCK enzymes affected by polymorphisms
The Thr431Asn polymorphism lies immediately carboxyl‐terminal to the start of the putative coiled‐coil region and encodes an amino acid substitution in the predicted coiled‐coil domain of the protein, which is associated with ROCK2/ROCK2 parallel homodimerization and Rho binding. Asp601Val polymorphism is also located on the coiled‐coil region. Because the dimeric structure of ROCK is essential for normal
Three
It has been reported that polymorphism can change the binding of the transcription factors to the gene. Pandey et al. [41] found that the variant allele rs10929728C of the
4. Conclusions
There are some inconsistent results with the association studies, which can be explained in part by population stratification, ethnic differences, selection bias, genotyping errors, or other factors. The incomplete polymorphism coverage likely does not represent the entire gene and therefore may not fully describe the contribution of
References
- 1.
Amano M, Nakayama M, Kaibuchi K. Rho‐kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken). 2010; 67 (9):545–554. DOI: 10.1002/cm.20472 - 2.
Julian L, Olson MF. Rho‐associated coiled‐coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014; 5 :e29846. DOI: 10.4161/sgtp.29846 - 3.
Komander D, Garg R, Wan PT, Ridley AJ, Barford D. Mechanism of multi‐site phosphorylation from a ROCK‐I:RhoE complex structure. The EMBO Journal. 2008; 27 (23):3175–3185. DOI: 10.1038/emboj.2008.226 - 4.
Doran JD, Liu X, Taslimi P, Saadat A, Fox T. New insights into the structure‐function relationships of Rho‐associated kinase: A thermodynamic and hydrodynamic study of the dimer‐to‐monomer transition and its kinetic implications. Biochemical Journal. 2004; 384 (Pt 2):255–262. DOI: 10.1042/BJ20040344 - 5.
Yamaguchi H, Kasa M, Amano M, Kaibuchi K, Hakoshima T. Molecular mechanism for the regulation of rho‐kinase by dimerization and its inhibition by fasudil. Structure. 2006; 14 (3):589–600. DOI: 10.1016/j.str.2005.11.024 - 6.
Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK‐I and ROCK‐II, two isoforms of Rho‐associated coiled‐coil forming protein serine/threonine kinase in mice. FEBS Letters. 1996; 392 (2):189–193. DOI: 10.1016/0014‐5793(96)00811‐3 - 7.
Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. Journal of Cardiovascular Disease Research. 2010; 1 (4):165–170. DOI: 10.4103/0975‐3583.74258 - 8.
Zhou Q, Gensch C, Liao JK. Rho‐associated coiled‐coil‐forming kinases (ROCKs): Potential targets for the treatment of atherosclerosis and vascular disease. Trends in Pharmacological Sciences. 2011; 32 (3):167–173. DOI: 10.1016/j.tips.2010.12.006 - 9.
Kalender ME, Demiryürek S, Oztuzcu S, Kizilyer A, Demiryürek AT, Sevinc A, Dikilitas M, Yildiz R, Camci C. Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer. Oncology Research. 2010; 18 (11–12):583–591. DOI: 10.3727/096504010X12767359113767 - 10.
Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010; 29 (17):2591–2598. DOI: 10.1038/onc.2010.3 - 11.
Cebrián A, Taron M, Sala N, Ardanaz E, Chirlaque MD, Larrañaga N, Redondo ML, Sánchez MJ, Gómez del Pulgar T, Camps C, Rosell R, González CA, Lacal JC. Variants in phospholipid metabolism and upstream regulators and non‐small cell lung cancer susceptibility. Clinical and Translational Oncology. 2014; 16 (1):107–112. DOI: 10.1007/s12094‐013‐1080‐7 - 12.
Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole‐exome sequencing of malignant ascites. Oncotarget. 2016; 7 (7):8055–8066. DOI: 10.18632/oncotarget.6977 - 13.
Sari I, Berberoglu B, Ozkara E, Oztuzcu S, Camci C, Demiryurek AT. Role of rho‐kinase gene polymorphisms and protein expressions in colorectal cancer development. Pathobiology. 2013; 80 (3):138–145. DOI: 10.1159/000341395 - 14.
Zucchini C, Martinelli M, De Sanctis P, Rodia MT, Mattei G, Ugolini G, Montroni I, Ghignone F, Solmi R. Possible gender‐related modulation by the ROCK1 gene in colorectal cancer susceptibility. Pathobiology. 2015; 82 (6):252–258. DOI: 10.1159/000439405 - 15.
Yanardag Acik D, Yılmaz M, Sarı I, Oztuzcu S, Sayıner ZA, Subari S, Demiryürek AT. Investigation of Rho‐kinase expressions and polymorphisms in mantle cell lymphoma patients. Turkish Journal of Hematology. 2016; 33 (2):141–147. DOI: 10.4274/tjh.2015.0193 - 16.
Zhao R, Liu K, Huang Z, Wang J, Pan Y, Huang Y, Deng X, Liu J, Qin C, Cheng G, Hua L, Li J, Yin C. Genetic variants in caveolin‐1 and RhoA/ROCK1 are associated with clear cell renal cell carcinoma risk in a Chinese population. PLoS One. 2015; 10 (6):e0128771. DOI: 10.1371/journal.pone.0128771 - 17.
Seasholtz TM, Wessel J, Rao F, Rana BK, Khandrika S, Kennedy BP, Lillie EO, Ziegler MG, Smith DW, Schork NJ, Brown JH, O’Connor DT. Rho kinase polymorphism influences blood pressure and systemic vascular resistance in human twins: Role of heredity. Hypertension. 2006; 47 (5):937–947. DOI: 10.1161/01.HYP.0000217364.45622.f0 - 18.
Rankinen T, Church T, Rice T, Markward N, Blair SN, Bouchard C. A major haplotype block at the rho‐associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: The HYPGENE study. Hypertension Research. 2008; 31 (8):1651–1657. DOI: 10.1291/hypres.31.1651 - 19.
Zhao Q, Wang L, Yang W, Chen S, Huang J, Fan Z, Li H, Lu X, Gu D. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenetics and Genomics. 2008; 18 (6):459–466. DOI: 10.1097/FPC.0b013e3282f97fb2 - 20.
Liu L, Cao Y, Cui G, Li Z, Sun J, Zhang L, Chen C, Wang Y, Wang P, Ding H, Wang DW. Association analysis of polymorphisms in ROCK2 with cardiovascular disease in a Chinese population. PLoS One. 2013; 8 (1):e53905. DOI: 10.1371/journal.pone.0053905 - 21.
Pandey P, Mohammad G, Singh Y, Pasha MA. Polymorphisms and haplotype of ROCK2 associate with high altitude essential hypertension in native high altitude Ladakhi Indian population: A preliminary study. Clinical and Experimental Hypertension. 2016; 38 (2):238–244. DOI: 10.3109/10641963.2015.1081231 - 22.
Peterson H, Laivuori H, Kerkelä E, Jiao H, Hiltunen L, Heino S, Tiala I, Knuutila S, Rasi V, Kere J, Kivinen K. ROCK2 allelic variants are not associated with pre‐eclampsia susceptibility in the Finnish population. Molecular Human Reproduction. 2009; 15 (7):443–449. DOI: 10.1093/molehr/gap032 - 23.
Ross KA. Evidence for somatic gene conversion and deletion in bipolar disorder, Crohn’s disease, coronary artery disease, hypertension, rheumatoid arthritis, type‐1 diabetes, and type‐2 diabetes. BMC Medicine. 2011; 9 :12. DOI: 10.1186/1741‐7015‐9‐12 - 24.
Liao YC, Liu PY, Lin HF, Lin WY, Liao JK, Juo SH. Two functional polymorphisms of ROCK2 enhance arterial stiffening through inhibiting its activity and expression. Journal of Molecular and Cellular Cardiology. 2015; 79 :180–186. DOI: 10.1016/j.yjmcc.2014.11.023 - 25.
Yoo SY, Kim J, Cheong S, Shin DH, Jang J, Lee C, Tahk SJ, Shin JH, Choi SY, Yoon MH. Rho‐associated kinase 2 polymorphism in patients with vasospastic angina. Korean Circulation Journal. 2012; 42 (6):406–413. DOI: 10.4070/kcj.2012.42.6.406 - 26.
Aksoy M, Uygun H, Baspinar O, Demiryurek S, Oztuzcu S, Cengiz B, Irdem A, Araz NC. Is there any association between childhood cardiac septal defects and ROCK2 gene polymorphism?. Genetics and Molecular Research. 2014; 13 (1):1949–1954. DOI: 10.4238/2014.March.17.22 - 27.
Palomino Doza J, Topf A, Bentham J, Bhattacharya S, Cosgrove C, Brook JD, Granados‐Riveron J, Bu’Lock FA, O’Sullivan J, Stuart AG, Parsons J, Relton C, Goodship J, Henderson DJ, Keavney B. Low‐frequency intermediate penetrance variants in the ROCK1 gene predispose to Tetralogy of Fallot. BMC Genetics. 2013; 14 :57. DOI: 10.1186/1471‐2156‐14‐57 - 28.
Pehlivan Y, Yolbas S, Cetin GY, Alibaz‐Oner F, Cagatay Y, Yilmaz N, Oztuzcu S, Donmez S, Ozgen M, Koca SS, Pamuk ON, Sayarlıoglu M, Kisacik B, Direskeneli H, Demiryurek AT, Onat AM. Investigation of the association between Rho/Rho‐kinase gene polymorphisms and systemic sclerosis. Rheumatology International. 2016; 36 (3):421–427. DOI: 10.1007/s00296‐015‐3400‐4 - 29.
Oguz E, Alasehirli B, Pehlivan Y, Onat AM, Oztuzcu S, Ozkara E, Kisacik B, Camci C, Demiryürek AT. Association between Rho‐kinase (ROCK2) gene polymorphisms and Behçet’s disease. Translational Research. 2012; 160 (6):428–434. DOI: 10.1016/j.trsl.2012.08.002 - 30.
Oguz E, Demiryürek AT, Pehlivan Y, Kisacik B, Ozkara E, Oztuzcu S, Alasehirli B, Onat AM. Association of Rho‐kinase 1 (ROCK1) gene polymorphisms with Behçet’s disease. Molecular Diagnosis & Therapy. 2014; 18 (4):419–426. DOI: 10.1007/s40291‐014‐0092‐5 - 31.
Demiryurek AT, Erbagci I, Oztuzcu S, Alasehirli B, Ozkara E, Seker M, Sönmez A, Ozsan M, Camci C. Lack of association between the Thr431Asn and Arg83Lys polymorphisms of the ROCK2 gene and diabetic retinopathy. Current Eye Research. 2010; 35 (12):1128–1134. DOI: 10.3109/02713683.2010.507903 - 32.
Demiryürek S, Okumus S, Bozgeyik İ, Oztuzcu S, Coskun E, Mat E, Durucu E, Tatar MG, Erbagci İ, Gürler B, Demiryürek AT. Investigation of the Rho‐kinase gene polymorphism in primary open‐angle glaucoma. Ophthalmic Genetics. 2016; 37 (1):9–13. DOI: 10.3109/13816810.2014.895016 - 33.
Zee RY, Wang QM, Chasman DI, Ridker PM, Liao JK. Gene variations of ROCKs and risk of ischaemic stroke: The Women’s Genome Health Study. Clinical Science (Lond). 2014; 126 (12):829–835. DOI: 10.1042/CS20130652 - 34.
Tabur S, Oztuzcu S, Oguz E, Korkmaz H, Eroglu S, Ozkaya M, Demiryürek AT. Association of Rho/Rho‐kinase gene polymorphisms and expressions with obesity‐related metabolic syndrome. European Review for Medical and Pharmacological Sciences. 2015; 19 (9):1680–1688 - 35.
Kaya G, Sivasli E, Oztuzcu S, Melekoglu NA, Ozkara E, Sarikabadayi U, Demiryürek AT. Association of Rho‐kinase gene polymorphisms with respiratory distress syndrome in preterm neonates. Pediatrics & Neonatology. 2017; 58 (1):36–42. DOI: 10.1016/j.pedneo.2015.12.006 - 36.
Yoshida T, Kato K, Yokoi K, Oguri M, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Nishigaki Y, Nozawa Y, Yamada Y. Association of genetic variants with chronic kidney disease in individuals with different lipid profiles. International Journal of Molecular Medicine. 2009; 24 (2):233–246. DOI: 10.3892/ijmm_00000226 - 37.
Rao F, Wessel J, Wen G, Zhang L, Rana BK, Kennedy BP, Greenwood TA, Salem RM, Chen Y, Khandrika S, Hamilton BA, Smith DW, Holstein‐Rathlou NH, Ziegler MG, Schork NJ, O’Connor DT. Renal albumin excretion: Twin studies identify influences of heredity, environment, and adrenergic pathway polymorphism. Hypertension. 2007; 49 :1015–1031. DOI: 10.1161/HYPERTENSIONAHA.106.081679 - 38.
Gurocak S, Konac E, Ure I, Senol C, Onen IH, Sozen S, Menevse A. The impact of gene polymorphisms on the success of anticholinergic treatment in children with overactive bladder. Disease Markers. 2015; 2015 :732686. DOI: 10.1155/2015/732686 - 39.
Yigiter R, Bozkurt H, Oztuzcu S, Demiryürek S, Demir T, Uslu Kuzudisli S, Yilmaz M, Demiryürek AT. No evidence for an association between ROCK2 gene Thr431Asn polymorphism and idiopathic generalized epilepsy: Preliminary findings. Journal of Neurological Sciences [Turkish]. 2013; 30 (3):494–501 - 40.
Uslu Kuzudisli S, Yilmaz M, Gül Z, Demiryürek S, Yigiter R, Bozkurt H, Akcali A, Neyal M, Bagci C, Cengiz B, Oztuzcu S, Demiryürek AT. Investigation of the Rho‐kinase 2 gene Thr431Asn polymorphism in migraine. Neurology India. 2014; 62 (1):9–14. DOI: 10.4103/0028‐3886.128241 - 41.
Pandey P, Mohammad G, Singh Y, Qadar Pasha MA. ROCK2 and MYLK variants under hypobaric hypoxic environment of high altitude associate with high altitude pulmonary edema and adaptation. The Application of Clinical Genetics. 2015; 8 :257–267. DOI: 10.2147/TACG.S90215 - 42.
Nakataki M, Numata S, Iga J, Tayoshi S, Tayoshi‐Shibuya S, Song H, Tanahashi T, Itakura M, Ueno S, Ohmori T. No association between Rho‐associated coiled‐coil forming protein serine/threonine kinase1 gene and schizophrenia in the Japanese population. Psychiatric Genetics. 2009; 19 (3):162. DOI: 10.1097/YPG.0b013e32832a5030 - 43.
Alhopuro P, Sammalkorpi H, Niittymäki I, Biström M, Raitila A, Saharinen J, Nousiainen K, Lehtonen HJ, Heliövaara E, Puhakka J, Tuupanen S, Sousa S, Seruca R, Ferreira AM, Hofstra RM, Mecklin JP, Järvinen H, Ristimäki A, Orntoft TF, Hautaniemi S, Arango D, Karhu A, Aaltonen LA. Candidate driver genes in microsatellite‐unstable colorectal cancer. International Journal of Cancer. 2012; 130 (7):1558–1566. DOI: 10.1002/ijc.26167 - 44.
Liu HW, Halayko AJ, Fernandes DJ, Harmon GS, McCauley JA, Kocieniewski P, McConville J, Fu Y, Forsythe SM, Kogut P, Bellam S, Dowell M, Churchill J, Lesso H, Kassiri K, Mitchell RW, Hershenson MB, Camoretti‐Mercado B, Solway J. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. American Journal of Respiratory Cell and Molecular Biology. 2003; 29 (1):39–47. DOI: 10.1165/rcmb.2002‐0206OC